Quest Diagnostics Inc vs Clear Secure Inc — how do they compare? Quest Diagnostics Inc trades at $231.03 (market cap $25.48B), while Clear Secure Inc trades at $43.47 (market cap $4.44B). The key difference: Quest Diagnostics Inc is far larger — about 5.7× Clear Secure Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Clear Secure Inc for 19 Days on average.
| DGX | YOU | |
|---|---|---|
Market Cap | $25.48B | $4.44B |
Volume | 941,866 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $247.45 | $62.36 |
52-Week Low | $173.49 | $29.61 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $31.23B | $3.59B |
Dividend Yield | 1.49% | 1.33% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Clear Secure (YOU) trades at $43.26, up 1.59% today, with a bullish technical signal despite mixed moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Profitability remains robust with a net margin of 14.78% and ROE of 90.29%, though valuation multiples like P/E of 29.11 appear elevated. Recent news highlights strategic partnerships, such as the integration with CrowdStrike's Falcon platform, and the launch of corporate memberships.
The outlook is positive given earnings momentum and expanding market opportunities, but risks include high valuation sensitivity and competitive pressures. Analysts are generally bullish with a consensus price target of $61.40, implying significant upside, though insider selling and overbought RSI levels warrant caution for near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →